J. Forbes

517 total citations
13 papers, 369 citations indexed

About

J. Forbes is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, J. Forbes has authored 13 papers receiving a total of 369 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 7 papers in Pulmonary and Respiratory Medicine and 4 papers in Cancer Research. Recurrent topics in J. Forbes's work include HER2/EGFR in Cancer Research (6 papers), Advanced Breast Cancer Therapies (5 papers) and Breast Cancer Treatment Studies (4 papers). J. Forbes is often cited by papers focused on HER2/EGFR in Cancer Research (6 papers), Advanced Breast Cancer Therapies (5 papers) and Breast Cancer Treatment Studies (4 papers). J. Forbes collaborates with scholars based in Canada, Ireland and United Kingdom. J. Forbes's co-authors include Martin Dennis, Steven Lewis, Gina Cranswick, H.T. Mouridsen, L. Mauriac, Aron Goldhirsch, Ian Smith, Robert Paridaens, Aparna Keshaviah and R.D. Gelber and has published in prestigious journals such as Journal of Clinical Oncology, British journal of surgery and Transplantation.

In The Last Decade

J. Forbes

13 papers receiving 353 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
J. Forbes Canada	7	132	93	83	81	71	13	369
Michaela Richardson United States	13	114 0.9×	59 0.6×	30 0.4×	60 0.7×	38 0.5×	27	561
Daniel K. Robie United States	14	60 0.5×	19 0.2×	93 1.1×	128 1.6×	64 0.9×	22	747
Estelle Le Pabic France	11	142 1.1×	27 0.3×	22 0.3×	85 1.0×	48 0.7×	42	385
Tibor Tihanyi Hungary	10	350 2.7×	18 0.2×	13 0.2×	141 1.7×	91 1.3×	28	549
Stephanie Davis United States	11	161 1.2×	42 0.5×	101 1.2×	271 3.3×	35 0.5×	23	838
Kunal C. Kadakia United States	13	208 1.6×	45 0.5×	57 0.7×	90 1.1×	47 0.7×	43	455
Yong‐Chen Chen Taiwan	11	80 0.6×	46 0.5×	21 0.3×	64 0.8×	44 0.6×	41	362
Dana M. Hayden United States	13	266 2.0×	71 0.8×	19 0.2×	85 1.0×	26 0.4×	44	644
Brian Herbst Germany	9	105 0.8×	41 0.4×	7 0.1×	56 0.7×	14 0.2×	18	548
Mirza I. Rahman United States	10	43 0.3×	52 0.6×	145 1.7×	48 0.6×	69 1.0×	18	379

Countries citing papers authored by J. Forbes

Since Specialization

Citations

This map shows the geographic impact of J. Forbes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Forbes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Forbes more than expected).

Fields of papers citing papers by J. Forbes

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. Forbes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Forbes. The network helps show where J. Forbes may publish in the future.

Co-authorship network of co-authors of J. Forbes

This figure shows the co-authorship network connecting the top 25 collaborators of J. Forbes. A scholar is included among the top collaborators of J. Forbes based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. Forbes. J. Forbes is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

Martín, Miguel, SA Hurvitz, John F. Kennedy, et al.. (2009). 5001 CIRG/TORI 010: first analysis of a randomized phase II trial of motesanib plus weekly paclitaxel (P) as first line therapy in HER2-negative metastatic breast cancer (MBC). European Journal of Cancer Supplements. 7(2). 260–260. 1 indexed citations

Coates, Alan S., J. Forbes, Jack Cuzick, et al.. (2008). Tamoxifen (TAM) for the prevention of breast cancer: Importance of specific aspects of health-related quality of life (HRQL) to global health status in the ANZ BCTG substudy of IBIS-1 (ANZ 92P1). Journal of Clinical Oncology. 26(15_suppl). 1516–1516. 2 indexed citations

Pegram, Mark D., J. Forbes, Tadeusz Pieńkowski, et al.. (2007). BCIRG 007: First overall survival analysis of randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin as first line therapy in HER2 amplified metastatic breast cancer (MBC). Journal of Clinical Oncology. 25(18_suppl). LBA1008–LBA1008. 30 indexed citations

Pieńkowski, Tadeusz, Mark D. Pegram, J. Forbes, et al.. (2007). 2098 ORAL BCIRG 007: First overall survival analysis of randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin as first line therapy in HER2 amplified metastatic breast cancer (MBC). European Journal of Cancer Supplements. 5(4). 212–213. 6 indexed citations

Forbes, J., Tadeusz Pieńkowski, Vicente Valero, et al.. (2006). BCIRG 007: Randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin first line in HER2 positive metastatic breast cancer (MBC). Journal of Clinical Oncology. 24(18_suppl). LBA516–LBA516. 21 indexed citations

Finn, Richard S., Judy Dering, Charles Ginther, et al.. (2006). ER+ PR- breast cancer defines a unique subtype of breast cancer that is driven by growth factor signaling and may be more likely to respond to EGFR targeted therapies. Journal of Clinical Oncology. 24(18_suppl). 514–514. 13 indexed citations

Dennis, Martin, Steven Lewis, Gina Cranswick, & J. Forbes. (2006). FOOD: a multicentre randomised trial evaluating feeding policies in patients admitted to hospital with a recent stroke. Health Technology Assessment. 10(2). iii–iv, ix. 114 indexed citations

Keshaviah, Aparna, H.T. Mouridsen, L. Mauriac, et al.. (2005). BIG 1–98: Randomized double-blind phase III study to evaluate letrozole (L) vs. tamoxifen (T) as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. Journal of Clinical Oncology. 23(16_suppl). 511–511. 88 indexed citations

McKillop, D., Holger Eidtmann, A. Riva, et al.. (2004). Intratumoral and plasma concentrations of gefitinib in breast cancer patients: Preliminary results from a presurgical investigatory study (BCIRG 103). Journal of Clinical Oncology. 22(14_suppl). 581–581. 11 indexed citations

10.

McKillop, D., et al.. (2004). Intratumoral and plasma concentrations of gefitinib in breast cancer patients: Preliminary results from a presurgical investigatory study (BCIRG 103). Journal of Clinical Oncology. 22(14_suppl). 581–581. 5 indexed citations

11.

Sandercock, Peter, Eivind Berge, Martin Dennis, et al.. (2002). A systematic review of the effectiveness, cost-effectiveness and barriers to implementation of thrombolytic and neuroprotective therapy for acute ischaemic stroke in the NHS. Health Technology Assessment. 6(26). 1–112. 70 indexed citations

12.

Hughes, L E & J. Forbes. (1978). Early breast cancer: Part II. Management. British journal of surgery. 65(11). 764–772. 5 indexed citations

13.

Forbes, J. & Peter J. Morris. (1972). THE USE OF LYMPH NODE AND SPLEEN LYMPHOCYTES FOR HL-A TYPING OF CADAVER KIDNEY DONORS. Transplantation. 13(4). 444–446. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact